BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its proprietary lipid nanocrystal (LNC) platform technology, announces that MAT2203, its oral LNC formulation of amphotericin B (AMB), will be featured in an oral company pipeline presentation at IDWeek, being held October 11-15 at the Boston Convention and Exhibition Center.
The presentation will be held as follows:
Title: | MAT2203, a Novel Oral Delivery of Amphotericin B (AMB), in Phase 3 Development for the Treatment of Invasive Fungal Infections |
Session: | New Antimicrobials in the Pipeline |
Date: | Thursday, October 12, 2023 at 8:12 a.m. Eastern time |
Location: | 104 ABC |
Speaker: | Theresa Matkovits, Ph.D., Chief Development Officer, Matinas |
"We are delighted to participate in this important scientific conference and to highlight additional clinical evidence from our Expanded Access Program supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections," said Dr. Matkovits. "The efficacy of AMB is well established, but use of this potent fungicidal drug is typically administered selectively and only to patients with severe disease because of its toxicity. MAT2203 reduces the systemic toxicity associated with IV AMB by delivering drug directly to targeted cells at the sites of infection, supporting a favorable safety profile with the additional benefit of oral administration.
"The compelling compassionate use data we will be presenting at IDWeek as part of our pipeline overview support our strategy to develop an ideal antifungal agent for the treatment ...